GlassScriptPhysician profile
Roland Oswald Willock
NPI 1053372920
$7,464.96
in general payments reported to CMS, 2019-2025
25 companies · $2,397 in 2025
The $2,397 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,657 · 2023: $952 · 2024: $2,459 · 2025: $2,397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,808.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,677.20 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,556.97 | 2022-2025 | Vraylar, Linzess, Ubrelvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $853.90 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $531.79 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Phathom Pharmaceuticals, INC. | $395.71 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $266.28 | 2022-2024 | Relistor |
| Pfizer INC. | $264.98 | 2023-2025 | |
| Ardelyx, INC. | $257.37 | 2023-2024 | Ibsrela |
| Janssen Pharmaceuticals, INC | $190.80 | 2022-2025 | Invega Sustenna, Spravato, Invega |
| Otsuka America Pharmaceutical, INC. | $185.46 | 2024-2025 | Rexulti |
| Almatica Pharma LLC | $152.71 | 2022-2024 | Loreev Xr, Gralise, Sertraline Hcl |
| Viiv Healthcare Company | $148.49 | 2024 | Apretude |
| Axsome Therapeutics, INC. | $144.98 | 2025 | Symbravo, Auvelity |
| Amgen INC. | $101.79 | 2022-2023 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.33 | 2023-2024 | Jardiance |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $98.58 | 2023-2025 | Zoryve, Seglentis |
| Aimmune Therapeutics, INC. | $73.03 | 2024-2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $72.09 | 2024 | |
| Novo Nordisk INC | $69.29 | 2022-2025 | Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $67.04 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $64.90 | 2022 | |
| Lundbeck LLC | $62.43 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $53.64 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Vanda Pharmaceuticals INC. | $45.40 | 2024 | Fanapt |
| Exact Sciences Corporation | $28.80 | 2023-2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roland Willock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.